Study Participants Participants aged 18 years, diagnosed with T2D, who were treatment-nave to injectable glucose-lowering drug(s) except for short-term insulin treatment for acute illness lasting for a total of 14 days, and who had an available HbA1c value within 90 days prior to visit (V) 1 or taken at V1 in line with local clinical practice, were included
For more information, watch the video below by Dr
Finally, the team determined safety and tolerability endpoints, e.g., drug-related adverse events, vitals, laboratory parameters, and electrocardiograms
Ongoing support : Remedy Meds provides continuous support from licensed healthcare providers, who can monitor your progress and adjust treatment as necessary
Politi, P